Market revenue in 2023 | USD 6.8 million |
Market revenue in 2030 | USD 10.5 million |
Growth rate | 6.4% (CAGR from 2023 to 2030) |
Largest segment | Bioavailability & bioequivalence studies |
Fastest growing segment | Bioavailability & Bioequivalence Studies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.29% in 2023. Horizon Databook has segmented the Denmark cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
Denmark’s biotechnology & pharmaceutical industry is one of the most innovative markets globally. It is a leader in drug development and offers attractive business solutions for international biotechnology companies. Companies are involved in R&D collaborations and several strategic alliances with research organizations & universities for faster approval or development of products in Europe.
Denmark conducts the highest number of clinical trials per capita globally. It is one of the most R&D-intensive countries and has a large concentration of researchers. The entrepreneurial ecosystem in Denmark is the fourth best in the world. Denmark is one of the countries that conducts clinical trials quickly, and it has several favorable framework conditions that make drug development and discovery safe, quick, & affordable.
Horizon Databook provides a detailed overview of country-level data and insights on the Denmark cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into Denmark cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account